These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30893889)

  • 21. Emerging applications of metabolomics in drug discovery and precision medicine.
    Wishart DS
    Nat Rev Drug Discov; 2016 Jul; 15(7):473-84. PubMed ID: 26965202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research into cancer metabolomics: Towards a clinical metamorphosis.
    Olivares O; Däbritz JHM; King A; Gottlieb E; Halsey C
    Semin Cell Dev Biol; 2015 Jul; 43():52-64. PubMed ID: 26365277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biotransformation-based metabolomics profiling method for determining and quantitating cancer-related metabolites.
    Yue X; He J; Zhang R; Xu J; Zhou Z; Zhang R; Bi N; Wang Z; Sun C; Wang L; Chen Y; Abliz Z
    J Chromatogr A; 2018 Dec; 1580():80-89. PubMed ID: 30473010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastric cancer: Metabolic and metabolomics perspectives (Review).
    Xiao S; Zhou L
    Int J Oncol; 2017 Jul; 51(1):5-17. PubMed ID: 28535006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Window of Opportunity trials for biomarker discovery in breast cancer.
    Arnedos M; Roulleaux Dugage M; Perez-Garcia J; Cortes J
    Curr Opin Oncol; 2019 Nov; 31(6):486-492. PubMed ID: 31464762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The metabolic landscape of cancer stem cells.
    Dando I; Dalla Pozza E; Biondani G; Cordani M; Palmieri M; Donadelli M
    IUBMB Life; 2015 Sep; 67(9):687-93. PubMed ID: 26337609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A review of validated biomarkers obtained through metabolomics.
    López-López Á; López-Gonzálvez Á; Barker-Tejeda TC; Barbas C
    Expert Rev Mol Diagn; 2018 Jun; 18(6):557-575. PubMed ID: 29808702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature.
    Poornima P; Kumar JD; Zhao Q; Blunder M; Efferth T
    Pharmacol Res; 2016 Sep; 111():290-302. PubMed ID: 27329331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omics-based biomarkers: current status and potential use in the clinic.
    Quezada H; Guzmán-Ortiz AL; Díaz-Sánchez H; Valle-Rios R; Aguirre-Hernández J
    Bol Med Hosp Infant Mex; 2017; 74(3):219-226. PubMed ID: 29382490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applications of metabolomics to study cancer metabolism.
    Kaushik AK; DeBerardinis RJ
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):2-14. PubMed ID: 29702206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.
    Tolstikov V; Nikolayev A; Dong S; Zhao G; Kuo MS
    PLoS One; 2014; 9(12):e114019. PubMed ID: 25486521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NMR-based metabolomics: translational application and treatment of cancer.
    Serkova NJ; Spratlin JL; Eckhardt SG
    Curr Opin Mol Ther; 2007 Dec; 9(6):572-85. PubMed ID: 18041668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
    Shang X; Zhong X; Tian X
    Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The metabolomic signature of hematologic malignancies.
    Allegra A; Innao V; Gerace D; Bianco O; Musolino C
    Leuk Res; 2016 Oct; 49():22-35. PubMed ID: 27526405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncometabolomics in cancer research.
    Gupta S; Chawla K
    Expert Rev Proteomics; 2013 Aug; 10(4):325-36. PubMed ID: 23992416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics.
    Serkova NJ; Niemann CU
    Expert Rev Mol Diagn; 2006 Sep; 6(5):717-31. PubMed ID: 17009906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue metabolic profiling of human gastric cancer assessed by (1)H NMR.
    Wang H; Zhang H; Deng P; Liu C; Li D; Jie H; Zhang H; Zhou Z; Zhao YL
    BMC Cancer; 2016 Jun; 16():371. PubMed ID: 27356757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of metabolomics in drug discovery and development.
    Wishart DS
    Drugs R D; 2008; 9(5):307-22. PubMed ID: 18721000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolomics Applications in Precision Medicine: An Oncological Perspective.
    Puchades-Carrasco L; Pineda-Lucena A
    Curr Top Med Chem; 2017; 17(24):2740-2751. PubMed ID: 28685691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.